STATES CHRONICLE – Anavex Corporation has been testing an Alzheimer’s drug, and they were waiting to reveal the results. Finally, they have announced positive results accomplished during the Alzheimer’s disease drug trial. On November 23, Anavex Life Sciences Corporation (AVXL) proved that their shares rose to about 10.29%, almost reaching $3.75. Approximately 1.97 million shares traded on 4,289 trades per day, whereas in the past the daily volume was about 1.44 million shares traded out of 35.71 million shares.
The market ca for Aanavex Life Sciences Corporation is approximate $133.92 million. This corporation represents a biopharmaceutical company bound to be in charge of drug’s clinical trials. The goal of this pharmaceutical company is to create drug candidates for a cure able to combat Alzheimer’s illness, many types of cancer and diseases which affect the central nervous system.
This corporation is located in New York, and it only has seven employees. The CEO of the company is Christopher U. Missling. The organization represents part of the Russell 2000. This is one of the major indices responsible for tracking small businesses based in the US.
Based on the data released by Anavex, the new drug proved to be successful demonstrating that Alzheimer’s patients who took an oral dose of ANAVEZ 2-73 every day have revealed signs of functional and cognitive measures’ stabilization. Due to the fact this disease is a progressive one, the new cure is promising, developing spectacular results.
The therapy used nowadays for Alzheimer’s patients is only meant to slow the progressive stages of the illness, but they are not able to stop its evolution. The Phase 2a ANAVEX 2-73 clinical trial is composed of two different stages, including the study of 32 Alzheimer’s patients which are all experiencing a variety of symptoms of the disease.
The first part consists of a two-period, open-label, cross-over between an administration of 30mg/ 50mg and IV 3mg/ 5mg, the trial unfolding during a period of five weeks for every patient. The second part of the trial represents an extension bound to last approximately 52 weeks. The goal which is intended to be reached at the end of the Phase 2a trial is to enable tolerability, safety and maximum tolerated doses of ANAVEX 2-73.
The maximum dose has proved to be promising during clinical studies, preventing the course of the disease.
Image courtesy of: wikipedia